Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Rodriguez-Mogeda C, van Lierop ZYGJ, van der Pol SMA, Coenen L, Hogenboom L, Kamermans A, Rodriguez E, van Horssen J, van Kempen ZLE, Uitdehaag BMJ, Teunissen CE, Witte ME, Killestein J, de Vries HE. Rodriguez-Mogeda C, et al. Among authors: hogenboom l. J Neuroinflammation. 2023 Sep 26;20(1):215. doi: 10.1186/s12974-023-02900-z. J Neuroinflammation. 2023. PMID: 37752582 Free PMC article.
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
Toorop AA, Hogenboom L, Bloem K, Kocyigit M, Commandeur NWM, Wijnants A, Lissenberg-Witte BI, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: hogenboom l. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):487-493. doi: 10.1136/jnnp-2022-330793. Epub 2023 Jan 24. J Neurol Neurosurg Psychiatry. 2023. PMID: 36693720
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.
van Dam KPJ, Hogenboom L, Stalman EW, Kummer LYL, Steenhuis M, Keijser JBD, Brinke AT, van Ham SM, Kuijpers TW, Rispens T, Wieske L, Eftimov F, Strijbis EM, Killestein J, van Kempen ZLE. van Dam KPJ, et al. Among authors: hogenboom l. Front Neurol. 2022 Nov 10;13:1032830. doi: 10.3389/fneur.2022.1032830. eCollection 2022. Front Neurol. 2022. PMID: 36438945 Free PMC article.
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
van Kempen ZLE, Hogenboom L, Toorop AA, Steenhuis M, Stalman EW, Kummer LYL, van Dam KPJ, Bloem K, Ten Brinke A, van Ham SM, Kuijpers TW, Wolbink GJ, Loeff FC, Wieske L, Eftimov F, Rispens T, Strijbis EMM, Killestein J; T2B! immunity against SARS-CoV-2 study group. van Kempen ZLE, et al. Among authors: hogenboom l. Ann Neurol. 2023 Jan;93(1):103-108. doi: 10.1002/ana.26534. Epub 2022 Nov 2. Ann Neurol. 2023. PMID: 36250739 Free PMC article.